Exelixis (NASDAQ: EXEL) fell 14% today after abstracts from the European Society for Medical Oncology (ESMO) meeting were released today.
Exelixis (NASDAQ: EXEL) fell 14% today after abstracts from the European Society for Medical Oncology (ESMO) meeting were released today.